about
The many faces of neuroendocrine differentiation in prostate cancer progressionHypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to HypoxiaHedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells.New insights into the role of EMT in tumor immune escape.Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.Oncogene-mediated alterations in chromatin conformationThe NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?Neuroendocrine differentiation in prostate cancer: from lab to bedside.Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells.Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis.Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.Increased expression of class III beta-tubulin in castration-resistant human prostate cancerLeft lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners.Protocadherin-PC promotes androgen-independent prostate cancer cell growth.Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells.A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy.Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance.Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity.Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and PlasticityProstate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillanceAXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
P50
Q26992049-94AAD6F6-4996-4830-8AC2-18932A75AFB8Q28085029-86852F78-9988-46D1-988D-449FA5DDDD7DQ33864161-57EE0E55-E91A-44B8-96F2-C16AB4567349Q33869781-C0938D95-F9D8-41FA-BB85-11C5D98F5E07Q33939310-B5E75B70-3D8C-4AD5-9429-3C3ADE40E8BEQ34007950-2318E184-BDCA-4850-B56A-52298DF55E1DQ34452282-23B42171-5B3C-416F-B99E-1B3383DAA8FEQ36061468-6266DF64-07C7-4C36-9310-BC359D454DA3Q36836686-B35C9982-4C6D-4FCE-AF3E-98FED7E5FF97Q37007889-15CBC7BB-416A-477C-9374-F8FF393359BBQ37688379-0205842A-7F9A-4B2E-A64D-DBA4963EF759Q39385550-63E5806D-4D2D-48A0-A11C-677131A716F3Q39434906-8D3C85BF-D0CD-45A9-8675-EC8FC04C96B5Q39438002-46AAA750-7BD9-4B1C-BAF5-E2111CED322EQ39636515-F9D43E5B-A226-4A04-AFD1-31417FAD7DB5Q39811005-998BE700-7151-41B8-9753-2D5C864523C9Q40170080-0F47F359-F4C9-4333-9C33-F803F6509AA6Q40287846-06E18FA4-6C0F-468C-8EED-A1EB15A0D179Q40317213-57D66A4D-BFA1-4441-8BD3-6D5DC730B9EAQ40408972-39A199C7-D8AF-42F9-850C-FD4B780A07B4Q42173139-B026FEA0-48AC-41F9-882B-071E2F52F8B5Q42653507-6C38DDA5-1BE6-4E21-AE31-5147AB2C8E32Q43431647-E1ACAE92-2000-4CE7-8D21-5CD948001F96Q44020742-4E934282-1657-473E-A13D-211E0BC309ACQ46690587-9552ED01-8A88-4034-B22A-425BBBA44B23Q47765499-3AE3C687-685B-4A47-9EA4-4CB4B92DB2DCQ52722403-0D1B03E5-70DF-4C09-B459-CA7879E47E89Q53399279-28218245-2E6A-466B-8578-AC26B9D5E2ADQ57296955-043E2120-C94B-426B-A1D6-BF3AB625D711Q82878808-BD120BD1-C3A4-481F-9557-1D234605ADA5Q93130623-B6015C1F-47A2-48CF-BFD5-DB3261EAC763
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stéphane Terry
@ast
Stéphane Terry
@en
Stéphane Terry
@es
Stéphane Terry
@nl
Stéphane Terry
@sl
type
label
Stéphane Terry
@ast
Stéphane Terry
@en
Stéphane Terry
@es
Stéphane Terry
@nl
Stéphane Terry
@sl
prefLabel
Stéphane Terry
@ast
Stéphane Terry
@en
Stéphane Terry
@es
Stéphane Terry
@nl
Stéphane Terry
@sl
P1053
K-5351-2013
P106
P21
P2798
P31
P3829
P496
0000-0003-3089-7886